Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 756

1.

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ.

Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14. Review.

PMID:
29540348
2.

Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia.

Law PJ, Berndt SI, Speedy HE, Camp NJ, Sava GP, Skibola CF, Holroyd A, Joseph V, Sunter NJ, Nieters A, Bea S, Monnereau A, Martin-Garcia D, Goldin LR, Clot G, Teras LR, Quintela I, Birmann BM, Jayne S, Cozen W, Majid A, Smedby KE, Lan Q, Dearden C, Brooks-Wilson AR, Hall AG, Purdue MP, Mainou-Fowler T, Vajdic CM, Jackson GH, Cocco P, Marr H, Zhang Y, Zheng T, Giles GG, Lawrence C, Call TG, Liebow M, Melbye M, Glimelius B, Mansouri L, Glenn M, Curtin K, Diver WR, Link BK, Conde L, Bracci PM, Holly EA, Jackson RD, Tinker LF, Benavente Y, Boffetta P, Brennan P, Maynadie M, McKay J, Albanes D, Weinstein S, Wang Z, Caporaso NE, Morton LM, Severson RK, Riboli E, Vineis P, Vermeulen RC, Southey MC, Milne RL, Clavel J, Topka S, Spinelli JJ, Kraft P, Ennas MG, Summerfield G, Ferri GM, Harris RJ, Miligi L, Pettitt AR, North KE, Allsup DJ, Fraumeni JF, Bailey JR, Offit K, Pratt G, Hjalgrim H, Pepper C, Chanock SJ, Fegan C, Rosenquist R, de Sanjose S, Carracedo A, Dyer MJ, Catovsky D, Campo E, Cerhan JR, Allan JM, Rothman N, Houlston R, Slager S.

Nat Commun. 2017 Feb 6;8:14175. doi: 10.1038/ncomms14175.

3.

Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci.

Law PJ, Sud A, Mitchell JS, Henrion M, Orlando G, Lenive O, Broderick P, Speedy HE, Johnson DC, Kaiser M, Weinhold N, Cooke R, Sunter NJ, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Carmichael J, Bailey JR, Pratt G, Rahman T, Pepper C, Fegan C, von Strandmann EP, Engert A, Försti A, Chen B, Filho MI, Thomsen H, Hoffmann P, Noethen MM, Eisele L, Jöckel KH, Allan JM, Swerdlow AJ, Goldschmidt H, Catovsky D, Morgan GJ, Hemminki K, Houlston RS.

Sci Rep. 2017 Jan 23;7:41071. doi: 10.1038/srep41071.

4.

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.

Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B.

Blood. 2017 Feb 2;129(5):553-560. doi: 10.1182/blood-2016-01-689422. Epub 2016 Nov 30.

5.

Non-coding NOTCH1 mutations in chronic lymphocytic leukemia; their clinical impact in the UK CLL4 trial.

Larrayoz M, Rose-Zerilli MJ, Kadalayil L, Parker H, Blakemore S, Forster J, Davis Z, Steele AJ, Collins A, Else M, Catovsky D, Oscier DG, Strefford JC.

Leukemia. 2017 Feb;31(2):510-514. doi: 10.1038/leu.2016.298. Epub 2016 Oct 26. No abstract available.

6.

Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia.

Speedy HE, Kinnersley B, Chubb D, Broderick P, Law PJ, Litchfield K, Jayne S, Dyer MJS, Dearden C, Follows GA, Catovsky D, Houlston RS.

Blood. 2016 Nov 10;128(19):2319-2326. doi: 10.1182/blood-2016-01-695692. Epub 2016 Aug 15.

7.

Genetic Predisposition to Chronic Lymphocytic Leukemia Is Mediated by a BMF Super-Enhancer Polymorphism.

Kandaswamy R, Sava GP, Speedy HE, Beà S, Martín-Subero JI, Studd JB, Migliorini G, Law PJ, Puente XS, Martín-García D, Salaverria I, Gutiérrez-Abril J, López-Otín C, Catovsky D, Allan JM, Campo E, Houlston RS.

Cell Rep. 2016 Aug 23;16(8):2061-2067. doi: 10.1016/j.celrep.2016.07.053. Epub 2016 Aug 11.

8.

The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial.

Oscier D, Else M, Matutes E, Morilla R, Strefford JC, Catovsky D.

Br J Haematol. 2016 Sep;174(5):767-75. doi: 10.1111/bjh.14132. Epub 2016 May 6.

9.

Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer.

Johnson N, De Ieso P, Migliorini G, Orr N, Broderick P, Catovsky D, Matakidou A, Eisen T, Goldsmith C, Dudbridge F, Peto J, Dos-Santos-Silva I, Ashworth A, Ross G, Houlston RS, Fletcher O.

Cancer Res. 2016 Mar 15;76(6):1485-1493. doi: 10.1158/0008-5472.CAN-15-1410.

10.

The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identity.

Davis Z, Forconi F, Parker A, Gardiner A, Thomas P, Catovsky D, Rose-Zerilli M, Strefford JC, Oscier D.

Br J Haematol. 2016 Apr;173(1):127-36. doi: 10.1111/bjh.13940. Epub 2016 Feb 5.

PMID:
26846718
11.

Evaluation of serum markers in the LRF CLL4 trial: β2-microglobulin but not serum free light chains, is an independent marker of overall survival.

Pratt G, Thomas P, Marden N, Alexander D, Davis Z, Hussey D, Parry H, Harding S, Catovsky D, Begley J, Oscier D.

Leuk Lymphoma. 2016 Oct;57(10):2342-50. doi: 10.3109/10428194.2015.1137291. Epub 2016 Feb 8.

PMID:
26732125
12.

Long-term follow-up after purine analogue therapy in hairy cell leukaemia.

Else M, Dearden CE, Catovsky D.

Best Pract Res Clin Haematol. 2015 Dec;28(4):217-29. doi: 10.1016/j.beha.2015.09.004. Epub 2015 Oct 9. Review.

13.

The long-term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years.

Else M, Wade R, Oscier D, Catovsky D.

Br J Haematol. 2016 Jan;172(2):228-37. doi: 10.1111/bjh.13824. Epub 2015 Oct 12.

14.

An unusual indication for splenectomy in hairy cell leukaemia: a report of three cases with persistent splenomegaly after chemoimmunotherapy.

Sarid N, Ahmad HN, Wotherspoon A, Dearden CE, Else M, Catovsky D.

Br J Haematol. 2015 Dec;171(5):784-7. doi: 10.1111/bjh.13767. Epub 2015 Sep 25.

15.

Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Robak T, Matutes E, Catovsky D, Zinzani PL, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2015 Sep;26 Suppl 5:v100-7. doi: 10.1093/annonc/mdv200. Epub 2015 Aug 12. No abstract available.

PMID:
26269205
16.

Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.

Strefford JC, Kadalayil L, Forster J, Rose-Zerilli MJ, Parker A, Lin TT, Heppel N, Norris K, Gardiner A, Davies Z, Gonzalez de Castro D, Else M, Steele AJ, Parker H, Stankovic T, Pepper C, Fegan C, Baird D, Collins A, Catovsky D, Oscier DG.

Leukemia. 2015 Dec;29(12):2411-4. doi: 10.1038/leu.2015.217. Epub 2015 Aug 10. No abstract available.

17.

Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk.

Sava GP, Speedy HE, Di Bernardo MC, Dyer MJ, Holroyd A, Sunter NJ, Marr H, Mansouri L, Deaglio S, Karabon L, Frydecka I, Jamroziak K, Woszczyk D, Juliusson G, Smedby KE, Jayne S, Majid A, Wang Y, Dearden C, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Rosenquist R, Catovsky D, Allan JM, Houlston RS.

Leukemia. 2015 Mar;29(3):748-51. doi: 10.1038/leu.2014.311. Epub 2014 Nov 3. No abstract available.

18.

The clinical significance of patients' sex in chronic lymphocytic leukemia.

Catovsky D, Wade R, Else M.

Haematologica. 2014 Jun;99(6):1088-94. doi: 10.3324/haematol.2013.101378. Epub 2014 Mar 21.

19.

ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.

Rose-Zerilli MJ, Forster J, Parker H, Parker A, Rodríguez AE, Chaplin T, Gardiner A, Steele AJ, Collins A, Young BD, Skowronska A, Catovsky D, Stankovic T, Oscier DG, Strefford JC.

Haematologica. 2014 Apr;99(4):736-42. doi: 10.3324/haematol.2013.098574. Epub 2014 Feb 28.

20.

A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia.

Speedy HE, Di Bernardo MC, Sava GP, Dyer MJ, Holroyd A, Wang Y, Sunter NJ, Mansouri L, Juliusson G, Smedby KE, Roos G, Jayne S, Majid A, Dearden C, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Rosenquist R, Catovsky D, Allan JM, Houlston RS.

Nat Genet. 2014 Jan;46(1):56-60. doi: 10.1038/ng.2843. Epub 2013 Dec 1.

PMID:
24292274
21.

CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia.

Johnson GG, Lin K, Cox TF, Oates M, Sibson DR, Eccles R, Lloyd B, Gardiner LJ, Carr DF, Pirmohamed M, Strefford JC, Oscier DG, Gonzalez de Castro D, Else M, Catovsky D, Pettitt AR.

Blood. 2013 Dec 19;122(26):4253-8. doi: 10.1182/blood-2013-07-516666. Epub 2013 Oct 15.

22.

rs2072135, a low-penetrance variant for chronic lymphocytic leukaemia?

Sava GP, Speedy HE, Di Bernardo MC, Deaglio S, Karabon L, Frydecka I, Woszczyk D, Rossi D, Gaidano G, Mansouri L, Smedby KE, Juliusson G, Rosenquist R, Catovsky D, Houlston RS.

Br J Haematol. 2013 Jul;162(2):221-8. doi: 10.1111/bjh.12366. Epub 2013 May 14.

PMID:
23668599
23.

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.

Oscier DG, Rose-Zerilli MJ, Winkelmann N, Gonzalez de Castro D, Gomez B, Forster J, Parker H, Parker A, Gardiner A, Collins A, Else M, Cross NC, Catovsky D, Strefford JC.

Blood. 2013 Jan 17;121(3):468-75. doi: 10.1182/blood-2012-05-429282. Epub 2012 Oct 18.

24.

Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma.

Else M, Marín-Niebla A, de la Cruz F, Batty P, Ríos E, Dearden CE, Catovsky D, Matutes E.

Br J Haematol. 2012 Nov;159(3):322-8. doi: 10.1111/bjh.12036. Epub 2012 Sep 27.

PMID:
23016878
25.

CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes.

Gonzalez D, Else M, Wren D, Usai M, Buhl AM, Parker A, Oscier D, Morgan G, Catovsky D.

Haematologica. 2013 Feb;98(2):274-8. doi: 10.3324/haematol.2012.070201. Epub 2012 Aug 16.

26.

Common genetic variation contributes significantly to the risk of developing chronic lymphocytic leukemia.

Di Bernardo MC, Broderick P, Catovsky D, Houlston RS.

Haematologica. 2013 Mar;98(3):e23-4. doi: 10.3324/haematol.2012.072140. Epub 2012 Aug 16. No abstract available.

27.

Risk of developing chronic lymphocytic leukemia is influenced by HLA-A class I variation.

Di Bernardo MC, Broderick P, Harris S, Dyer MJ, Matutes E, Dearden C, Catovsky D, Houlston RS.

Leukemia. 2013 Jan;27(1):255-8. doi: 10.1038/leu.2012.173. Epub 2012 Jul 2. No abstract available.

28.

The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry.

Matutes E, Bosanquet AG, Wade R, Richards SM, Else M, Catovsky D.

Leukemia. 2013 Feb;27(2):507-10. doi: 10.1038/leu.2012.209. Epub 2012 Jul 19. No abstract available.

29.

Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia.

Slager SL, Skibola CF, Di Bernardo MC, Conde L, Broderick P, McDonnell SK, Goldin LR, Croft N, Holroyd A, Harris S, Riby J, Serie DJ, Kay NE, Call TG, Bracci PM, Halperin E, Lanasa MC, Cunningham JM, Leis JF, Morrison VA, Spector LG, Vachon CM, Shanafelt TD, Strom SS, Camp NJ, Weinberg JB, Matutes E, Caporaso NE, Wade R, Dyer MJ, Dearden C, Cerhan JR, Catovsky D, Houlston RS.

Blood. 2012 Jul 26;120(4):843-6. doi: 10.1182/blood-2012-03-413591. Epub 2012 Jun 13.

30.

Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.

Lin K, Adamson J, Johnson GG, Carter A, Oates M, Wade R, Richards S, Gonzalez D, Matutes E, Dearden C, Oscier DG, Catovsky D, Pettitt AR.

Clin Cancer Res. 2012 Aug 1;18(15):4191-200. doi: 10.1158/1078-0432.CCR-11-2936. Epub 2012 Jun 6.

31.

The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma.

Hockley SL, Else M, Morilla A, Wotherspoon A, Dearden C, Catovsky D, Gonzalez D, Matutes E.

Br J Haematol. 2012 Aug;158(3):347-54. doi: 10.1111/j.1365-2141.2012.09163.x. Epub 2012 May 18.

PMID:
22594855
32.

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.

Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, Johnson GG, Schuh A, Matutes E, Dearden CE, Catovsky D, Radford JA, Bloor A, Follows GA, Devereux S, Kruger A, Blundell J, Agrawal S, Allsup D, Proctor S, Heartin E, Oscier D, Hamblin TJ, Rawstron A, Hillmen P.

J Clin Oncol. 2012 May 10;30(14):1647-55. doi: 10.1200/JCO.2011.35.9695. Epub 2012 Apr 9.

PMID:
22493413
33.

Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial.

Else M, Cocks K, Crofts S, Wade R, Richards SM, Catovsky D, Smith AG; UK National Cancer Research Institute (NCRI) Chronic Lymphocytic Leukaemia Trials Group.

Leuk Lymphoma. 2012 Jul;53(7):1289-98. doi: 10.3109/10428194.2011.649479. Epub 2012 Mar 1.

PMID:
22168274
34.

Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*.

Jones G, Parry-Jones N, Wilkins B, Else M, Catovsky D; British Committee for Standards in Haematology.

Br J Haematol. 2012 Jan;156(2):186-95. doi: 10.1111/j.1365-2141.2011.08931.x. Epub 2011 Nov 24.

PMID:
22111844
35.

Chlorambucil--still not bad: a reappraisal.

Catovsky D, Else M, Richards S.

Clin Lymphoma Myeloma Leuk. 2011 Jun;11 Suppl 1:S2-6. doi: 10.1016/j.clml.2011.02.006. Epub 2011 May 6.

PMID:
22035743
36.

Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route.

Dearden CE, Khot A, Else M, Hamblin M, Grand E, Roy A, Hewamana S, Matutes E, Catovsky D.

Blood. 2011 Nov 24;118(22):5799-802. doi: 10.1182/blood-2011-08-372854. Epub 2011 Sep 26.

37.

Association between single nucleotide polymorphism-genotype and outcome of patients with chronic lymphocytic leukemia in a randomized chemotherapy trial.

Wade R, Di Bernardo MC, Richards S, Rossi D, Crowther-Swanepoel D, Gaidano G, Oscier DG, Catovsky D, Houlston RS.

Haematologica. 2011 Oct;96(10):1496-503. doi: 10.3324/haematol.2011.043471. Epub 2011 Jun 9.

38.

A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial.

Dearden CE, Richards S, Else M, Catovsky D, Hillmen P.

Cancer. 2011 Jun 1;117(11):2452-60. doi: 10.1002/cncr.25776. Epub 2010 Dec 14.

39.

Long-term results for pentostatin and cladribine treatment of hairy cell leukemia.

Dearden CE, Else M, Catovsky D.

Leuk Lymphoma. 2011 Jun;52 Suppl 2:21-4. doi: 10.3109/10428194.2011.565093. Review.

PMID:
21599603
40.

Common genetic variation at 15q25.2 impacts on chronic lymphocytic leukaemia risk.

Crowther-Swanepoel D, Di Bernardo MC, Jamroziak K, Karabon L, Frydecka I, Deaglio S, D'Arena G, Rossi D, Gaidano G, Olver B, Lloyd A, Broderick P, Laurenti L, Szemraj-Rogucka Z, Robak T, Catovsky D, Houlston RS.

Br J Haematol. 2011 Jul;154(2):229-33. doi: 10.1111/j.1365-2141.2011.08706.x. Epub 2011 May 9.

PMID:
21554262
41.

Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence.

Else M, Dearden CE, Matutes E, Forconi F, Lauria F, Ahmad H, Kelly S, Liyanage A, Ratnayake V, Shankari J, Whalley I, Catovsky D.

Leuk Lymphoma. 2011 Jun;52 Suppl 2:75-8. doi: 10.3109/10428194.2011.568650. Epub 2011 Apr 19.

PMID:
21504288
42.

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.

Gonzalez D, Martinez P, Wade R, Hockley S, Oscier D, Matutes E, Dearden CE, Richards SM, Catovsky D, Morgan GJ.

J Clin Oncol. 2011 Jun 1;29(16):2223-9. doi: 10.1200/JCO.2010.32.0838. Epub 2011 Apr 11.

PMID:
21483000
43.

High-resolution genomic profiling in hairy cell leukemia-variant compared with typical hairy cell leukemia.

Hockley SL, Morgan GJ, Leone PE, Walker BA, Morilla A, Else M, Wotherspoon A, Dearden C, Catovsky D, Gonzalez D, Matutes E.

Leukemia. 2011 Jul;25(7):1189-92. doi: 10.1038/leu.2011.47. Epub 2011 Mar 25. No abstract available.

PMID:
21436839
44.

Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation.

Michallet M, Dreger P, Sutton L, Brand R, Richards S, van Os M, Sobh M, Choquet S, Corront B, Dearden C, Gratwohl A, Herr W, Catovsky D, Hallek M, de Witte T, Niederwieser D, Leporrier M, Milligan D; EBMT Chronic Leukemia Working Party.

Blood. 2011 Feb 3;117(5):1516-21. doi: 10.1182/blood-2010-09-308775. Epub 2010 Nov 24.

45.

Inherited genetic susceptibility to monoclonal B-cell lymphocytosis.

Crowther-Swanepoel D, Corre T, Lloyd A, Gaidano G, Olver B, Bennett FL, Doughty C, Toniolo D, Caligaris-Cappio F, Ghia P, Rossi D, Rawstron AC, Catovsky D, Houlston RS.

Blood. 2010 Dec 23;116(26):5957-60. doi: 10.1182/blood-2010-07-294975. Epub 2010 Sep 20. Erratum in: Blood. 2011 Mar 24;117(12):3477. Calligaris-Cappio, Federico [corrected to Caligaris-Cappio, Federico].

46.

Diagnostic issues in chronic lymphocytic leukaemia (CLL).

Matutes E, Attygalle A, Wotherspoon A, Catovsky D.

Best Pract Res Clin Haematol. 2010 Mar;23(1):3-20. doi: 10.1016/j.beha.2010.01.001. Review.

PMID:
20620967
47.

Verification that common variation at 2q37.1, 6p25.3, 11q24.1, 15q23, and 19q13.32 influences chronic lymphocytic leukaemia risk.

Crowther-Swanepoel D, Mansouri M, Enjuanes A, Vega A, Smedby KE, Ruiz-Ponte C, Jurlander J, Juliusson G, Montserrat E, Catovsky D, Campo E, Carracedo A, Rosenquist R, Houlston RS.

Br J Haematol. 2010 Aug;150(4):473-9. doi: 10.1111/j.1365-2141.2010.08270.x. Epub 2010 Jun 10.

PMID:
20553269
48.

Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation.

Oscier D, Wade R, Davis Z, Morilla A, Best G, Richards S, Else M, Matutes E, Catovsky D; Chronic Lymphocytic Leukaemia Working Group, UK National Cancer Research Institute.

Haematologica. 2010 Oct;95(10):1705-12. doi: 10.3324/haematol.2010.025338. Epub 2010 May 29.

49.

Higher expression levels of activation-induced cytidine deaminase distinguish hairy cell leukemia from hairy cell leukemia-variant and splenic marginal zone lymphoma.

Hockley SL, Morilla A, Else M, Dearden C, Catovsky D, Morgan GJ, Matutes E, Gonzalez D.

Leukemia. 2010 May;24(5):1084-6. doi: 10.1038/leu.2010.44. Epub 2010 Mar 18. No abstract available.

PMID:
20237507
50.

Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study.

Krishnan B, Else M, Tjonnfjord GE, Cazin B, Carney D, Carter J, Ketterer N, Catovsky D, Ethell M, Matutes E, Dearden CE.

Br J Haematol. 2010 Jun;149(6):907-10. doi: 10.1111/j.1365-2141.2010.08134.x. Epub 2010 Mar 1. No abstract available.

PMID:
20201944

Supplemental Content

Loading ...
Support Center